BioPharmSignal logoBioPharmSignal

Biotech News

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

Aziyo Biologics (AZYO)Aziyo BiologicsCommercial

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x,

Related news

AZYOAziyo Biologics2026-08-18 12:00 EST

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

AZYOAziyo Biologics2026-07-16 20:05 EST

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

View all latest news

Aziyo Biologics

Drug-Eluting Biomatrix Company Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site. Antibiotic-Eluting Platform The company's biomatrix technology incorporates antibiotics into a biologic scaffold. The platform was first...

Recent company news

AZYOAziyo Biologics2026-08-18 12:00 EST

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

AZYOAziyo Biologics2026-08-13 20:10 EST

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

AZYOAziyo Biologics2026-08-13 20:05 EST

Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

AZYOAziyo Biologics2026-07-31 12:00 EST

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

AZYOAziyo Biologics2026-07-16 20:05 EST

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States